Q-omics provides the consensus-scored LCN15 profile across patient tissues and cancer cell-line models. LCN15 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LCN15 is differentially expressed in 10, with the highest sampling consensus in UCEC. Additionally, LCN15 RNA expression shows 10,228 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, UCEC, and GBM as cancer lineages where LCN15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCN15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCN15 survival associations across molecular data types. LCN15 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCN15 RNA expression–survival associations across cancer types. High LCN15 expression shows unfavorable associations in KIRC, DLBC, ACC and KIRP, but favorable associations in THCA and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for LCN15 RNA expression.
This table summarizes LCN15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LCN15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCN15 shows lower tumor expression in BRCA, KICH, PRAD and HNSC and higher tumor expression in UCEC and THCA. The UCEC box plot shows higher LCN15 RNA expression in tumor versus normal tissue (log2 FC = +0.704, t-test p < 0.001).
This table shows molecular features associated with LCN15 in patient tissues and cancer cell lines. In patient samples, LCN15 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, LCN15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_SCLC.
